FIBROLAMELLAR CARCINOMA
Clinical trials for FIBROLAMELLAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR CARCINOMA trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: immunotherapy trial targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 16, 2026 22:32 UTC
-
New drug cocktail shows promise for kids with rare cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with solid tumors that have come back or not responded to treatment. The goal is to find safe doses and see if the drugs shrink tumors. The trial…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for kids with tough liver cancer: immunotherapy trial opens
Disease control Recruiting nowThis study tests the drug pembrolizumab (Keytruda) in children and young adults up to age 30 whose liver cancer has come back or not responded to treatment. The goal is to see if the drug can shrink tumors or slow the disease. About 18 participants will receive the immunotherapy,…
Matched conditions: FIBROLAMELLAR CARCINOMA
Phase: PHASE2 • Sponsor: Allison O'Neill, MD • Aim: Disease control
Last updated May 07, 2026 18:40 UTC